Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects

Sung Yong Lee, Tae Heung Kang, Jayne Knoff, Zhuomin Huang, Ruey Shyang Soong, Ronald D. Alvarez, Chien-Fu Hung, Tzyy Choou Wu

Research output: Contribution to journalArticle

Abstract

Despite the conventional treatments of radiation therapy and chemotherapy, the 5-year survival rates for patients with advanced-stage cervical cancers remain low. Cancer immunotherapy has emerged as an alternative, innovative therapy that may improve survival. Here, we utilize a preclinical HPV-16 E6/E7-expressing tumor model, TC-1, and employ the chemotherapeutic agent cisplatin to generate an accumulation of CD11c+ dendritic cells in tumor loci making it an ideal location for the administration of therapeutic vaccines. Following cisplatin treatment, we tested different routes of administration of a therapeutic HPV vaccinia vaccine encoding HPV-16 E7 antigen (CRT/E7-VV). We found that TC-1 tumor-bearing C57BL/6 mice treated with cisplatin and intratumoral injection of CRT/E7-VV significantly increased E7-specific CD8+ T cells in the blood and generated potent local and systemic antitumor immune responses compared to mice receiving cisplatin and CRT/E7-VV intraperitoneally or mice treated with cisplatin alone. We further extended our study using a clinical grade recombinant vaccinia vaccine encoding HPV-16/18 E6/E7 antigens (TA-HPV). We found that intratumoral injection with TA-HPV following cisplatin treatment also led to increased E7-specific CD8+ T cells in the blood as well as significantly decreased tumor size compared to intratumoral injection with wild type vaccinia virus. Our study has strong implications for future clinical translation using intratumoral injection of TA-HPV in conjunction with the current treatment strategies for patients with advanced cervical cancer.

Original languageEnglish (US)
Pages (from-to)1175-1185
Number of pages11
JournalCancer Immunology Immunotherapy
Volume62
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

Papillomavirus Vaccines
Vaccinia
Cisplatin
Injections
Human papillomavirus 16
Neoplasms
Uterine Cervical Neoplasms
Therapeutics
T-Lymphocytes
Antigens
Human papillomavirus 18
Investigational Therapies
Synthetic Vaccines
Vaccinia virus
Complementary Therapies
Inbred C57BL Mouse
Immunotherapy
Dendritic Cells
Radiotherapy
Vaccines

Keywords

  • Cisplatin
  • Human papillomavirus
  • TA-HPV
  • Vaccine
  • Vaccinia virus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. / Lee, Sung Yong; Kang, Tae Heung; Knoff, Jayne; Huang, Zhuomin; Soong, Ruey Shyang; Alvarez, Ronald D.; Hung, Chien-Fu; Wu, Tzyy Choou.

In: Cancer Immunology Immunotherapy, Vol. 62, No. 7, 07.2013, p. 1175-1185.

Research output: Contribution to journalArticle

Lee, Sung Yong ; Kang, Tae Heung ; Knoff, Jayne ; Huang, Zhuomin ; Soong, Ruey Shyang ; Alvarez, Ronald D. ; Hung, Chien-Fu ; Wu, Tzyy Choou. / Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. In: Cancer Immunology Immunotherapy. 2013 ; Vol. 62, No. 7. pp. 1175-1185.
@article{5873f70d265e4fcfb6aa871216afa12b,
title = "Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects",
abstract = "Despite the conventional treatments of radiation therapy and chemotherapy, the 5-year survival rates for patients with advanced-stage cervical cancers remain low. Cancer immunotherapy has emerged as an alternative, innovative therapy that may improve survival. Here, we utilize a preclinical HPV-16 E6/E7-expressing tumor model, TC-1, and employ the chemotherapeutic agent cisplatin to generate an accumulation of CD11c+ dendritic cells in tumor loci making it an ideal location for the administration of therapeutic vaccines. Following cisplatin treatment, we tested different routes of administration of a therapeutic HPV vaccinia vaccine encoding HPV-16 E7 antigen (CRT/E7-VV). We found that TC-1 tumor-bearing C57BL/6 mice treated with cisplatin and intratumoral injection of CRT/E7-VV significantly increased E7-specific CD8+ T cells in the blood and generated potent local and systemic antitumor immune responses compared to mice receiving cisplatin and CRT/E7-VV intraperitoneally or mice treated with cisplatin alone. We further extended our study using a clinical grade recombinant vaccinia vaccine encoding HPV-16/18 E6/E7 antigens (TA-HPV). We found that intratumoral injection with TA-HPV following cisplatin treatment also led to increased E7-specific CD8+ T cells in the blood as well as significantly decreased tumor size compared to intratumoral injection with wild type vaccinia virus. Our study has strong implications for future clinical translation using intratumoral injection of TA-HPV in conjunction with the current treatment strategies for patients with advanced cervical cancer.",
keywords = "Cisplatin, Human papillomavirus, TA-HPV, Vaccine, Vaccinia virus",
author = "Lee, {Sung Yong} and Kang, {Tae Heung} and Jayne Knoff and Zhuomin Huang and Soong, {Ruey Shyang} and Alvarez, {Ronald D.} and Chien-Fu Hung and Wu, {Tzyy Choou}",
year = "2013",
month = "7",
doi = "10.1007/s00262-013-1421-y",
language = "English (US)",
volume = "62",
pages = "1175--1185",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "7",

}

TY - JOUR

T1 - Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects

AU - Lee, Sung Yong

AU - Kang, Tae Heung

AU - Knoff, Jayne

AU - Huang, Zhuomin

AU - Soong, Ruey Shyang

AU - Alvarez, Ronald D.

AU - Hung, Chien-Fu

AU - Wu, Tzyy Choou

PY - 2013/7

Y1 - 2013/7

N2 - Despite the conventional treatments of radiation therapy and chemotherapy, the 5-year survival rates for patients with advanced-stage cervical cancers remain low. Cancer immunotherapy has emerged as an alternative, innovative therapy that may improve survival. Here, we utilize a preclinical HPV-16 E6/E7-expressing tumor model, TC-1, and employ the chemotherapeutic agent cisplatin to generate an accumulation of CD11c+ dendritic cells in tumor loci making it an ideal location for the administration of therapeutic vaccines. Following cisplatin treatment, we tested different routes of administration of a therapeutic HPV vaccinia vaccine encoding HPV-16 E7 antigen (CRT/E7-VV). We found that TC-1 tumor-bearing C57BL/6 mice treated with cisplatin and intratumoral injection of CRT/E7-VV significantly increased E7-specific CD8+ T cells in the blood and generated potent local and systemic antitumor immune responses compared to mice receiving cisplatin and CRT/E7-VV intraperitoneally or mice treated with cisplatin alone. We further extended our study using a clinical grade recombinant vaccinia vaccine encoding HPV-16/18 E6/E7 antigens (TA-HPV). We found that intratumoral injection with TA-HPV following cisplatin treatment also led to increased E7-specific CD8+ T cells in the blood as well as significantly decreased tumor size compared to intratumoral injection with wild type vaccinia virus. Our study has strong implications for future clinical translation using intratumoral injection of TA-HPV in conjunction with the current treatment strategies for patients with advanced cervical cancer.

AB - Despite the conventional treatments of radiation therapy and chemotherapy, the 5-year survival rates for patients with advanced-stage cervical cancers remain low. Cancer immunotherapy has emerged as an alternative, innovative therapy that may improve survival. Here, we utilize a preclinical HPV-16 E6/E7-expressing tumor model, TC-1, and employ the chemotherapeutic agent cisplatin to generate an accumulation of CD11c+ dendritic cells in tumor loci making it an ideal location for the administration of therapeutic vaccines. Following cisplatin treatment, we tested different routes of administration of a therapeutic HPV vaccinia vaccine encoding HPV-16 E7 antigen (CRT/E7-VV). We found that TC-1 tumor-bearing C57BL/6 mice treated with cisplatin and intratumoral injection of CRT/E7-VV significantly increased E7-specific CD8+ T cells in the blood and generated potent local and systemic antitumor immune responses compared to mice receiving cisplatin and CRT/E7-VV intraperitoneally or mice treated with cisplatin alone. We further extended our study using a clinical grade recombinant vaccinia vaccine encoding HPV-16/18 E6/E7 antigens (TA-HPV). We found that intratumoral injection with TA-HPV following cisplatin treatment also led to increased E7-specific CD8+ T cells in the blood as well as significantly decreased tumor size compared to intratumoral injection with wild type vaccinia virus. Our study has strong implications for future clinical translation using intratumoral injection of TA-HPV in conjunction with the current treatment strategies for patients with advanced cervical cancer.

KW - Cisplatin

KW - Human papillomavirus

KW - TA-HPV

KW - Vaccine

KW - Vaccinia virus

UR - http://www.scopus.com/inward/record.url?scp=84879555379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879555379&partnerID=8YFLogxK

U2 - 10.1007/s00262-013-1421-y

DO - 10.1007/s00262-013-1421-y

M3 - Article

VL - 62

SP - 1175

EP - 1185

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 7

ER -